Recent Treatments for Multiple Sclerosis

The owner of CLM Global Enterprises, LLC, Carmine Fusco has a proven track record of success in financial investments, accounting, finance, and insurance. Carmine Fusco is also interested in following recent developments on multiple sclerosis (MS), as he faces his own battle with the disease.

MS is an unpredictable illness that attacks the central nervous system. In some patients, MS can be somewhat benign, while for others, it can be disabling. It is a disease in which the communication from the brain to the other parts of the body can be disrupted.

Despite the technological advancements nowadays, MS remains incurable. However, the National Institute of Neurological Disorders and Stroke (NINDS) has been in the pursuit of finding new or better therapeutic solutions to MS. One of the most promising thus far involves the discovery of interferons, a naturally-occurring antiviral protein.

It has been found that beta interferons can decrease the occurrence of relapse. Beta interferons were also found to delay the progress of physical disability. When attacks occur, they were less severe and shorter. There are a number of other therapies and treatments undergoing investigation aimed at improving function or curtailing attacks.

Meanwhile, the US Food and Drug Administration (FDA) has approved several prescriptive medicines that can treat one or more types of MS, either by minimizing the occurrence of attacks, treating relapses, or delaying the progress of the disease. The most recent FDA-approved drugs were siponimod tablets, used to treat relapses. The FDA approved the tablets in March 2019. Other FDA-approved beta interferon medicines include Betaseron, Avonex, Refib, and Extavia.